トポイソメラーゼ阻害薬
関連文献

“Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance”. Cancer Res. 67 (21):  10397–405. (Nov 2007). doi:10.1158/0008-5472.can-07-0938. PMID 17974983.
“Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity”. Mol. Pharmacol. 70 (3):  1109–1120. (2006). doi:10.1124/mol.106.024372. PMID 16798938.
“Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison”. Mol. Pharmacol. 67 (2):  523–30. (Feb 2005). doi:10.1124/mol.104.003889. PMID 15531731.
“Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.”. Cancer Res. 63 (21):  7428–35. (Nov 2003). PMID 14612542.
“Activity of indenoisoquinolines against African trypanosomes”. Antimicrob. Agents Chemother. 53 (1):  123–8. (Jan 2009). doi:10.1128/aac.00650-07. PMC 2612167. PMID 18824603. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612167/.
“Topoisomerase II inactivation prevents the completion of DNA replication in budding yeast”. Molecular Cell 30 (6):  790–802. (Jun 2008). doi:10.1016/j.molcel.2008.04.019. PMID 18570880.
“Topoisomerase levels determine chemotherapy response in vitro and in vivo”. Proc. Natl. Acad. Sci. USA 105 (26):  9053–8. (Jul 2008). Bibcode: 2008PNAS..105.9053B. doi:10.1073/pnas.0803513105. PMC 2435590. PMID 18574145. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2435590/.
“Design, docking, and synthesis of novel indeno[1,2-c]isoquinolines for the development of antitumor agents as topoisomerase I inhibitors”. Bioorg. Med. Chem. Lett. 17 (13):  3531–4. (Jul 2007). doi:10.1016/j.bmcl.2007.04.064. PMID 17498951.
“Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships”. Bioorg. Med. Chem. 17 (20):  7145–55. (Oct 2009). doi:10.1016/j.bmc.2009.08.066. PMC 2769207. PMID 19783447. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769207/.
“The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode”. Bioorg. Med. Chem. 18 (15):  5535–52. (Aug 2010). doi:10.1016/j.bmc.2010.06.040. PMC 2911012. PMID 20630766. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911012/.
“Design, synthesis, and biological evaluation of 14-substituted aromathecins as Topoisomerase I inhibitors”. J. Med. Chem. 51 (15):  4609–19. (Aug 2008). doi:10.1021/jm800259e. PMC 2538619. PMID 18630891. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538619/.
“Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors”. J. Med. Chem. 43 (20):  3688–98. (Oct 2000). doi:10.1021/jm000029d. PMID 11020283.
“Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776”. J. Pharm. Biomed. Anal. 52 (5):  714–20. (Sep 2010). doi:10.1016/j.jpba.2010.02.020. PMC 2865235. PMID 20236781. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865235/.
“Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis”. J. Med. Chem. 48 (15):  4803–14. (2005). doi:10.1021/jm050076b. PMID 16033260.
“Development of a validated immunofluorescence assay for yH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity”. Clin. Cancer Res. 16 (22):  5447–57. (Nov 2010). doi:10.1158/1078-0432.ccr-09-3076. PMC 2982895. PMID 20924131. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982895/.
“Design, synthesis, and evaluation of dibenzo[c,h[1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents”]. J. Med. Chem. 53 (24):  8716–26. (Dec 2010). doi:10.1021/jm101048k. PMC 3064471. PMID 21090809. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064471/.
“A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of topoisomerase I-DNA covalent complexes”. Mol. Cancer Ther. 5 (2):  287–95. (Feb 2006). doi:10.1158/1535-7163.mct-05-0456. PMC 2860177. PMID 16505102. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860177/.
“Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors”. J. Med. Chem. 50 (18):  4388–404. (Sep 2007). doi:10.1021/jm070307+. PMID 17676830.
“Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization”. J. Med. Chem. 50 (18):  4419–30. (Sep 2007). doi:10.1021/jm070361q. PMID 17696418.
“Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay”. Bioorg. Med. Chem. Lett. 16 (16):  4395–9. (Aug 2006). doi:10.1016/j.bmcl.2006.05.048. PMID 16750365.
“Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors”. J. Med. Chem. 49 (17):  5129–40. (Aug 2006). doi:10.1021/jm060046o. PMID 16913702.
“Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen”. J. Med. Chem. 46 (26):  5712–24. (2003). doi:10.1021/jm030313f. PMID 14667224.
“Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity”. Mol. Cancer Ther. 8 (7):  1878–84. (Jul 2009). doi:10.1158/1535-7163.mct-09-0016. PMC 2728499. PMID 19584232. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728499/.
“The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives”. Mol. Cancer Ther. 8 (5):  1008–14. (May 2009). doi:10.1158/1535-7163.mct-08-0706. PMC 2888777. PMID 19383846. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888777/.
“DNA topoisomerases and their poisoning by anticancer and antibacterial drugs”. Chem. Biol. 17 (5):  421–33. (May 2010). doi:10.1016/j.chembiol.2010.04.012. PMC 7316379. PMID 20534341. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316379/.
Pommier Y (Jul 2009). “DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition”. Chem. Rev. 109 (7):  2894–902. doi:10.1021/cr900097c. PMC 2707511. PMID 19476377. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707511/.
Pommier Y (2006). “Topoisomerase I inhibitors: camptothecins and beyond”. Nat. Rev. Cancer 6 (10):  789–802. doi:10.1038/nrc1977. PMID 16990856. https://zenodo.org/record/1233494.
Pommier Y (2004). “Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints”. Curr. Med. Chem. Anti-Cancer Agents 4 (5):  429–34. doi:10.2174/1568011043352777. PMID 15379698.
“Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors”. J. Med. Chem. 53 (5):  1979–89. (Mar 2010). doi:10.1021/jm901649x. PMC 2838169. PMID 20155916. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838169/.
“Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission”. J. Biol. Chem. 283 (34):  23200–8. (Aug 2008). doi:10.1074/jbc.m801146200. PMC 2516995. PMID 18556653. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2516995/.
“Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex”. J. Med. Chem. 48 (7):  2336–45. (Apr 2005). doi:10.1021/jm049146p. PMID 15801827.
Teicher BA (2008). “Next generation topoisomerase I inhibitors: rationale and biomarker strategies”. Biochem. Pharmacol. 75 (6):  1262–71. doi:10.1016/j.bcp.2007.10.016. PMID 18061144.
“Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives”. Bioorg. Med. Chem. 16 (6):  3153–62. (2008). doi:10.1016/j.bmc.2007.12.028. PMID 18180162.
“Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription”. Nat. Cell Biol. 11 (11):  1315–24. (Nov 2009). doi:10.1038/ncb1984. PMC 2912930. PMID 19838172. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912930/.
Van HT, Le QM, Lee KY, Lee ES, Kwon Y, Kim TS, Le TN, Lee SH, Cho WJ (Nov 2007). “Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex”. Bioorg Med Chem Lett 17 (21):  5763–7. doi:10.1016/j.bmcl.2007.08.062. PMID 17827007.
Nagarajan M.; Morrell A.; Ioanoviciu A.; Antony S.; Kohlhagen G.; Hollingshead M.; Pommier Y.; Cushman M. (2006). “Synthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen Heterocycles”. J. Med. Chem. 49 (21):  6283–6289. doi:10.1021/jm060564z. PMC 2526314. PMID 17034134. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526314/.